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DeNIS collaboration: 
setting the future 
research agenda
We salute the huge efforts of the 
DeNIS collaboration (October, 2016).1 
Their study not only comprehensively 
sets the scene for neonatal sepsis and 
antimicrobial re sistance in a low-
income and middle-income setting 
but also, by highlighting gaps in our 
understanding of neonatal sepsis 
and antimicrobial resistance, sets the 
future research agenda.
The absence of a globally accepted 
single standard deﬁ nition of multidrug 
resistance is a key issue.2,3 Diﬃ  culties in 
showing a clear relationship between 
antimicrobial resistance and outcomes 
might reﬂ ect the absence of clinical 
relevance of currently used deﬁ nitions. 
Standardised deﬁ nitions for multidrug 
resistance, which account for infection 
type, age, and key risk factors, are now 
needed.
The high rates of Acinetobacter and 
coagulase-negative staphylococcal 
infections among the pathogens 
causing early-onset sepsis are striking, 
but additionally they emphasise 
the absence of validated deﬁ nitions 
for clinical sepsis.4 Knowledge of 
the clinical features and outcomes 
associated with such cases and 
their correlation with those of more 
established pathogens, as well as non-
infected control babies, might help our 
understanding of their relevance and 
aid in validating new deﬁ nitions.
The study1 reported high rates of 
antimicrobial resistance and also 
reminds us of the paucity of new drugs 
to treat such infections, especially in 
neonates, as well as the paucity of data 
on antimicrobial pharmacokinetics 
in this population. Observational and 
interventional multicentre studies 
are needed to establish the safety 
and efficacy of new regimens and 
antibiotics (targeted at antimicrobial-
resistant pathogens) compared with 
existing combinations, together with 
new strategies for using them wisely.5 
Further study in low-income and 
middle-income countries is required 
and the DeNIS collaboration is a 
landmark step in this direction.
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